References
- Arnon S, Grigg J, Silverman M. Effectiveness of budesonide aerosol in ventilator dependent preterm babies: A preliminary report. Pediatr Pulmonol 1996; 21: 231–235
- Arya V, DeMarco VG, Issar M, et al. Brain permeability of corticosteroids in neonatal rats. Tampa, FL 2003
- Attar MA, Donn SM. Mechanisms of ventilator-induced lung injury in premature infants. Sem Neonatol 2002; 7: 353–360
- Bancalari E. Corticosteroids and neonatal chronic lung disease. Eur J Pediatr 1998; 157(Supp 1)S31–S37
- Brattsand R, Axelsson BI. Basis of airway selectivity of inhaled glucocorticoids. Inhaled glucocorticoids in asthma. Macel Dekker, New York 1997; 351–379
- Chanoine F, Grenot C, Heidmann P, et al. Pharmacokinetics of butixocort 21 propionate budesonide and beclomethasone dipropionate in the rat after intratracheal, intravenous and oral treatments. Drug Metab Dispos 1991; 19(2)546–553
- Clark RH, Gerstmann DR, Jobe AH, et al. Lung injury in neonates: Causes, strategies for prevention and long term consequences. J Pediatr 2001; 139(4)478–486
- Dimitriou G, Greenough A, Giffin FJ. Inhaled vs. systemic steroids in chronic oxygen dependency of preterm infants. Eur J Pediatr 1997; 156: 51–55
- Georgieff MK, Mammel MC, Mills MM, et al. Effect of postnatal steroid administration on serum vitamin A concentrations in new born infants with respiratory compromise. J Pediatr 1989; 114: 301–304
- Gonzalez-Rothi RJ, Suarez S, Hochhaus G, et al. Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 1996; 13: 1699–1703
- Groneck P, Reuss D, Speer BG, et al. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J Pediatr 1993; 122: 938–944
- Groneck P, Speer BG, Speer BG. Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease. Pediatr Pulmonol 1999; 27: 383–387
- Hochhaus G, Coowanitwong I, Kim S-K. Ultrathin coatings for pulmonary drug delivery. Materials Research Society, Boston 2001
- Hochhaus G, Gonzalez Rothi R, Lukyanov A, et al. Assessment of glucocorticoid lung targeting by ex vivo receptor binding studies in rats. Pharm Res 1995; 12(1)134–137
- Hochhaus G, Mollmann H, Derendorf H, et al. Pharmacokinetic-pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997; 37: 881–892
- Jonsson B, Eriksson M, Soder O, et al. Budesonide delivered by dosimetric jet nebulization to preterm very low birthweight infants at high risk for development of chronic lung disease. Acta Paediatr 2000; 1449(55)1449–1455
- Matsuoka Y, Okazaki M, Kitamura Y, et al. Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J Neurobiol 1999; 39: 383–392
- Papile LA, Stoll B, Donovan E, et al. Dexamethasone therapy in infants at risk for chronic lung disease (CLD): A multicenter, randomized, double-masked trial. Pediatr Res 1996; 39: 236A
- Ryrfeldt A, Andersson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63(Suppl 122)86–95
- Singh RK, Kim WS, Ollinger M, et al. Laser based systhesis of nanofunctionalized particulates for pulmonary based controlled drug delivery applications. Appl Surf Sci 2002; 197–198: 610–614
- Stark AR, Carlo WA, Tyson J, et al. Adverse effects of early dexamethasone treatment in extremely-low-birth- weight infants. N Engl J Med 2001; 344: 95–101
- Stefely J. Novel excipients for inhalation drug delivery: Expanding the capability of the MDI. Drug Deliv Technol 2002; 2: 62–69
- Talton JD, Fetz-Gerald J, Singh RK, et al. Nanothin coatings for improved lung targeting of glucocorticoid dry powders: In vitro and in vivo characteristics. Respir Drug Deliv 2000; 7: 67–74
- Yeh TF, Lin CH, Huang CC, et al. Early dexamethasone therapy in preterm infants: A follow-up study. Pediatrics 1998; 101: E7